Sysmex Corporation (6869.T) fair value

ACCE thesis

Sysmex makes the hematology analyzers that run complete blood counts in hospital and reference labs, along with the reagents and consumables those machines burn through, so most of its revenue is recurring once an instrument is installed. Its moat is that installed base and the switching cost of re-validating a lab's workflow around a competitor's platform, which tends to keep customers in place for years. Revenue grew 23.6% over the period in the data, a pace well above what a mature diagnostics franchise usually delivers, and gross margin of 51.0% suggests the mix is holding up. The stock trades at 30.7 times trailing earnings but 18.6 times forward, a gap that implies the market expects earnings to catch up with sales, and 11.3% operating margin is the number to test against that expectation. Low ROE of 8.3% alongside that growth warrants a closer look at how much of the equity base is absorbed by acquisitions or working capital before the thesis is taken seriously.